Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Roots of clinical resistance to STI-571 cancer therapy.

× No keyword cloud information.

17 in total

Review 1. Applying the discovery of the Philadelphia chromosome.

Authors: Daniel W Sherbenou; Brian J Druker
Journal: J Clin Invest Date: 2007-08 Impact factor: 14.808

Review 2. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors: Bertrand Rochat
Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447

3. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Authors: Nicholas C Wolff; Darren R Veach; William P Tong; William G Bornmann; Bayard Clarkson; Robert L Ilaria
Journal: Blood Date: 2005-01-18 Impact factor: 22.113

Review 4. Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.

Authors: Mohammad Azam; George Q Daley
Journal: Mol Diagn Ther Date: 2006 Impact factor: 4.074

5. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.

Authors: Ping-Hui Tseng; Ho-Pi Lin; Jiuxiang Zhu; Kuen-Feng Chen; Erinn M Hade; Donn C Young; John C Byrd; Michael Grever; Kara Johnson; Brian J Druker; Ching-Shih Chen
Journal: Blood Date: 2005-01-21 Impact factor: 22.113

6. Usefulness of quantitative assessment of JunB gene expression as a marker for monitoring chronic myeloid leukemia patients undergoing imatinib therapy.

Authors: Yi-Chang Liu; Hui-Hua Hsiao; Jan-Gowth Chang; Ming-Yu Yang; Ta-Chih Liu; Chao-Song Chang; Shih-Bin Tseng; Huei-Jen Tsai; Sheng-Fung Lin
Journal: Int J Hematol Date: 2006-12 Impact factor: 2.490

7. Stochastic dynamics of leukemic cells under an intermittent targeted therapy.

Authors: Nicola Pizzolato; Dominique Persano Adorno; Davide Valenti; Bernardo Spagnolo
Journal: Theory Biosci Date: 2011-04-09 Impact factor: 1.919

8. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia.

Authors: Olivier Kretz; H Markus Weiss; Martin M Schumacher; Gerhard Gross
Journal: Br J Clin Pharmacol Date: 2004-08 Impact factor: 4.335

Review 9. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Authors: Chikashi Yoshida; Junia V Melo
Journal: Int J Hematol Date: 2004-06 Impact factor: 2.490

10. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.

Authors: Hardik Modi; Tinisha McDonald; Su Chu; Jiing-Kuan Yee; Stephen J Forman; Ravi Bhatia
Journal: Blood Date: 2007-03-08 Impact factor: 22.113